Valbenazine (Ingrezza) is used primarily for the treatment of which condition?

Valbenazine, marketed as Ingrezza, is specifically indicated for the treatment of tardive dyskinesia, a condition characterized by involuntary, repetitive body movements that can occur in patients who have been treated with certain antipsychotic medications over an extended period. The mechanism of action of valbenazine involves the selective inhibition of the vesicular monoamine transporter 2 (VMAT2), which helps to decrease the excessive dopamine release that is thought to contribute to the symptoms of tardive dyskinesia.

In contrast, while dystonia and acute akathisia are movement disorders, they are treated with different medications that target their specific pathophysiology. Neuroleptic malignant syndrome is a serious reaction to antipsychotic medications that usually requires immediate medical intervention rather than standard treatment for tardive dyskinesia. Thus, valbenazine’s targeted action and clinical studies affirm its use primarily for tardive dyskinesia, making this the correct answer.